GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Acorda Therapeutics, Inc. (ACOR) [hlAlert]

Rating:
Overweight
ACOR
up 30.35 %

Acorda Therapeutics, Inc. (ACOR) upgraded to Overweight by Piper Jaffray

Posted on: Wednesday,  Aug 5, 2009  8:25 AM ET by Piper Jaffray

Piper Jaffray rated Overweight Acorda Therapeutics, Inc. (NASDAQ: ACOR) on 08/05/2009, when the stock price was $24.31. Since
then, Acorda Therapeutics, Inc. has gained 30.36% as of 01/26/2016's recent price of $31.69.
If you would have followed this Piper Jaffray's recommendation on ACOR, you would have gained 30.35% of your investment in 2365 days.

Acorda Therapeutics is commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the central nervous system. Acorda currently markets Zanaflex Capsules for the management of spasticity. The Company's lead product candidate, Fampridine-SR, for the improvement of walking ability in persons with multiple sclerosis. It develops therapies that restore neurological function to people with spinal cord injury, multiple sclerosis and related conditions of the nervous system.

At Piper Jaffray, we understand there’s no substitute for relevant and timely research. That's why we provide: * fundamental and technical research * value-added investment ideas * market analysis With the information our research team provides, you’ll make better and more informed decisions for your portfolio.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
8/5/2009 8:25 AM Buy
None
24.31
as of 12/31/2009
1 Week down  -7.20 %
1 Month down  -0.45 %
3 Months up  2.96 %
1 YTD down  -1.39 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
7/1/2009 8:25 AM Hold
None
25.47

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy